Trial Update Out on Sedar51 phase 2 patients treated. Of the 43 evaluable patients CR at any time = 60% and total responders = 77% Of the 29 patients evaluated at 450 days 28% were CR and total responders = 38%
Animal studies will continue throughout 2023 using a new light activation platform - the TLC-3000B - to determine if the vaccine will prevent animals from getting Covid.